At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 164 enrolled
Drug / intervention
carfilzomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating carfilzomib for Multiple Myeloma. Completed, enrolled 164 participants across 30 sites in 2 countries.
Detailed Summary
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionJan 2013
Study CompletionJul 2013
TodayJul 2026
First PostedSep 18, 2007
Enrollment StartSep 1, 2007
Primary CompletionJan 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.8 years ago
Interventions
carfilzomibdrug
Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.